Roundtable Dinner Series

---

This roundtable series zeroes in on the highest‑impact use‑case in AI imaging today: real‑time detection and triage of acute stroke on CT/CTA/CT‑Perfusion. Discussion topics include integration with telestroke platforms, alert fatigue mitigation, ROI modeling for hospital administrators, and best practices from stroke centers already live on AI.

This program zooms past “weight‑loss hype” to the real game‑changer: how GLP‑1/GIP agents re‑wire cardiometabolic risk. We’ll unpack the SELECT and SURMOUNT data, practical dosing escalations, payer landmines, and how to integrate remote monitoring. Discussion hits protocol design for obesity medicine, cardiology, and endocrinology clinics.

Heart‑failure readmissions are the single costliest penalty line on every value‑based scorecard. This roundtable digs into remote‑patient‑monitoring (RPM) workflows that cut bounce‑backs by 35 %+. We’ll dissect best‑in‑class sensor stacks, set‑up of a nurse‑command center, alert fatigue governance, and how to plug the data feed into MSSP & Medicare Advantage risk contracts. 

America’s sharpest mental‑health pain‑point is no longer adult burnout—it’s the adolescent crisis. This dinner drills into evidence‑based digital solutions for youth depression, anxiety, ADHD, and suicidality: FDA‑cleared digital therapeutics, AI‑driven CBT chatbots, text‑based coaching, and hybrid tele‑psychiatry that plugs straight into school systems and Medicaid plans. 

IVF success now hinges less on volume and more on data fidelity. This dinner dives into the cutting‑edge intersection of computer‑vision embryo grading, non‑invasive genetic screening, and fully automated culture systems. We’ll unpack how deep‑learning models score morphokinetics, correlate with PGT‑A results, and raise live‑birth rates without lengthening time‑to‑transfer.

Tumor boards are shifting from “treat‑all” to treat‑on‑signal, and circulating‑tumor‑DNA minimal‑residual‑disease (ctDNA‑MRD) assays are the trigger. This dinner unpacks how tumor‑informed NGS platforms (Signatera, Reveal, FoundationOne Tracker) detect relapse 6–12 months before imaging, guide adjuvant escalation for high‑risk signal‑positive patients, and spare signal‑negative patients from toxic overtreatment. 

Now that ex vivo CRISPR cures for sickle‑cell and β‑thalassemia have FDA green lights (and $2‑3 M price tags), the next frontier is in vivo editing for ATTR amyloidosis, DMD, and beyond. We’ll dissect patient‑selection algorithms, long‑term off‑target surveillance, payer carve‑outs, and the operational reality of one‑and‑done therapies that still need lifetime monitoring. Surgeons, heme‑onc physicians, and payers leave knowing how to integrate CRISPR into care pathways without detonating budgets

Whole‑slide scanners and deep‑learning QC are slashing slide turnaround from days to hours while unlocking remote subspecialty reads. We’ll unpack CAP validation protocols, LIS integrations, and how community hospitals can monetize overflow consults instead of outsourcing them. Attendees get a blueprint for capital budgeting, storage requirements, and AI overlap detection.

Continuous ECG patches, smart‑watch algorithms, and AI triage dashboards are surfacing silent AF earlier and pushing same‑day anticoag starts. We’ll cover FDA De Novo clearances, device‑to‑EP hand‑off inside 24 h, and how to bill RPM without drowning nurses in alerts. Clinicians leave with a turnkey care‑path; device makers leave with pilot commitments and data‑sharing partners.

Live‑biotherapeutic products are through the FDA gate for recurrent C. difficile; ulcerative colitis and metabolic‑syndrome indications are next. Discussion tackles sourcing donor material, cold‑chain economics, payer dossiers, and how to fold these drugs into antimicrobial‑stewardship programs without supply nightmares. IDS physicians, GI docs, and pharmacy directors walk away prepped to launch; sponsors capture formulary decision‑maker intel.

Evidence‑backed PRP, bone‑marrow concentrate, and next‑gen scaffolds now delay knee and shoulder replacements by 3‑5 years. We’ll clarify FDA 361 HCT/P rules, compare cash‑pay vs. insurer pathways, and review MRI‑based outcomes that justify employer‑sponsored bundles. Ortho surgeons and sports‑medicine docs get a protocol they can bill tomorrow; device firms get usage data and real‑world endpoints they crave.

CPAP‑compliance dashboards, mandibular‑advancement wearables, and FDA‑cleared CBT‑i apps are turning sleep labs into virtual service lines. We’ll drill into AHI remote monitoring, DME logistics, and payer arguments that link improved compliance to lower AFib and hypertension claims. Sleep specialists, ENT, and primary‑care leaders gain a one‑evening roadmap; sponsors get direct channel access to prescribers controlling device spend.

Point‑of‑care PGx panels covering CYP2C19, CYP2D6, and SLCO1B1 genes are cutting trial‑and‑error in CV and psych meds. We’ll show how to embed CDS hooks in Epic/Cerner, fight payer PA hurdles, and quantify avoided ER visits in MSSP contracts. PCPs leave with a PGx launch kit; labs and platform vendors leave with practice groups ready to onboard.

CMS waiver programs now reimburse hospital‑level care for CHF, COPD, and post‑op infection entirely at home. We’ll break down nurse‑command center build‑outs, rapid‑response logistics, virtual rounding, and margin math versus med‑surg beds. Hospitalists, CFOs, and home‑health execs walk out with an implementation timeline; tech and supply vendors secure live pilots.

Hand‑held ultrasound is now frontline for sepsis, tamponade, and DVT—but only if clinicians are credentialed and images flow to PACS. We’ll outline training tracks, CPT billing, AI auto‑annotation, and fleet management that stops probes from walking off. ED, critical‑care, and anesthesiology chiefs leave ready to scale POCUS; device makers leave with volume buyers and feedback to refine next‑gen probes.